ChartRow logo
Data provided bySource: Twelve Data
BMRN
$58.51+0.90%
as of close, Nov 17, 2026
☾ AH $58.51 +0.90%
Share this page

BMRN — BioMarin Pharmaceutical Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in BMRN be worth today? →
BMRN returns: By year · By month · By week · Trailing

Price data

Price
$58.51
YTD price return
-1.55%
YTD total return
-1.55%
Market cap
11.3B
Enterprise value
14.8B
Shares outstanding
193.7M
52W low
$49.26
52W high
$70.98
From 52W high
-17.57%
From 52W low
+18.78%
52W range
43%$49.26–$70.98
Beta
0.23

Volume

Rel volume
0.92×
30D volume
2.4M
30D $ vol
137.5M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
−$1.2M
Insider net 1Y
−$4.3M

Form 4 transactions by trade date, as filed; latest on file 2026-09-02.

Fundamentals

Sales (ttm)
3.7B
Sales/share
$18.87
EPS (ttm)
-$0.10
FCF (ttm)
557.9M
FCF/share
$2.88
Book value/share
$32.30
Net margin
-0.52%
ROE
-0.31%
ROA
-0.17%
Debt / equity
0.56×
Current ratio
2.44

Growth (CAGR, ttm) · 10Y

Sales
+18.15%+16.51%+14.61%+13.34%
FCF
-32.98%+151.37%+25.10%n/a
Shares
+0.82%+0.93%+1.08%+1.20%

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+17.18%+15.44%+13.39%+12.00%
FCF/share
-33.53%+149.05%+23.77%n/a
Book value/share
+2.45%+7.50%+6.81%+7.70%
Price
+7.44%-12.56%-6.24%-4.15%
Total return
+7.44%-12.56%-6.24%-4.15%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-600.4×
P/OI (ttm)
99.5×
Fwd P/E
9.0×
P/S (ttm)
3.1×
P/B (mrq)
1.8×
P/FCF (ttm)
20.3×
EV/EBITDA (fy)
39.1×
EV/Sales (ttm)
4.1×
FCF yield (ttm)
4.92%
Buyback yield (realized, 1y)
-0.82%
Shareholder yield (realized, 1y)
-0.82%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/E
69th
P/OI
62nd
P/S
2nd
P/B
8th
P/FCF
28th

Bar = where today’s multiple sits in BMRN’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
+0.90%
5D
+2.42%
1M
+7.00%
3M
-12.20%
YTD
-1.55%
1Y
+7.44%
5Y
-27.53%
1D
+0.90%
5D
+2.42%
1M
+7.00%
3M
-12.20%
YTD
-1.55%
1Y
+7.44%
5Y
-27.53%

Fundamentals#

Revenue

5Y CAGR +11.6%10Y CAGR +13.7%YoY +32.0%
$3.7B TTM$1B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m
$113.9M TTM−$82.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR −16.7%10Y n/mYoY n/m
−$0.10 TTM−$0.63 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY −53.0%
$557.9M TTM$159.9M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $676.6M, capex −$118.8M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $188.2M, capex −$28.3M

Shares (diluted)

5Y +3.0%10Y +23.4%YoY +0.8%
196.2M TTM193.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR −16.4%10Y n/mYoY n/m
−$19.1M TTM−$122.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full BMRN financials →

About BioMarin Pharmaceutical#

Data provided bySource: Twelve Data

BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement therapies, gene therapies, and other specialized biologics designed for patients living with genetically defined conditions. BioMarin’s products are used in areas including lysosomal storage disorders, achondroplasia, hemophilia, phenylketonuria, and other serious rare diseases. The company serves a specialized role in the healthcare market by addressing conditions that often have limited treatment options, with a business model centered on research, regulatory development, manufacturing, and global commercialization of orphan-disease therapies. Headquartered in San Rafael, California, BioMarin Pharmaceutical Inc. is recognized as a leading rare disease biotechnology company.

San Rafael, CA·3,221 employees·Biotechnology·biomarin.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding BMRN#

22 of the 193 ETFs ChartRow carries live hold BMRN. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
XBISPDR S&P Biotech ETF0.9%
IBBiShares Biotechnology ETF0.8%
VBKVanguard Small-Cap Growth ETF0.3%
IJHiShares Core S&P Mid-Cap ETF0.3%
MDYSPDR S&P MidCap 400 ETF Trust0.3%
VHTVanguard Health Care ETF0.2%
VBVanguard Small-Cap ETF0.1%
VXFVanguard Extended Market ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%